DESCRIPTION:
FiteBac® K18/MMA
10% K18 formulated in liquid MMA
INDICATIONS FOR USE
Liquid MMA component for
2-part acrylate system
TARGET AUDIENCE:
Dental Laboratories
DEVELOPMENT STATUS:
Cleared for use in dental acrylics
PLANNED COMMERCIAL INTRODUCTION:
Q1/2019
BENEFITS:
Manufacture of dentures and retainers with long term antimicrobial resistance to biofilm formation.
DESCRIPTION:
FiteBac® Cavity Cleanser
2% K21 QAS aqueous ethanolic solution
INDICATIONS FOR USE
Intended for cleansing and moistening/re-wetting of cavity preparations
TARGET AUDIENCE:
Prescritpion use for dental professionals
DEVELOPMENT STATUS:
Under FDA Review
Q1/2018
PLANNED COMMERCIAL INTRODUCTION:
Q3/2019
BENEFITS:
Remove debris in carious lesion preparations but can penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface
DESCRIPTION:
FiteBac® OrthoBond
5% K18 in a temporary orthodontic dental adhesive
INDICATIONS FOR USE
Temporarily placement of orthodontic appliances
TARGET AUDIENCE:
Dental Offices
DEVELOPMENT STATUS:
510(k) Submission
Q2/2019
PLANNED COMMERCIAL INTRODUCTION:
Q4/2019
BENEFITS:
Resistance to biofilm formation around and under orthodontic brackets. Reduce risk of surface damage to surface enamel of teeth. Improved cosmetic outcomes.
DESCRIPTION:
FiteBac® FT Bond
5% K18 in a permanent acrylic based dental adhesive
INDICATIONS FOR USE
Permanent placement of dental appliances and restorations
TARGET AUDIENCE:
Dental Offices
DEVELOPMENT STATUS:
510(k) submission
Q2/2019
PLANNED COMMERCIAL INTRODUCTION:
Q4/2019
BENEFITS:
Resistance to biofilm formation, loss of adhesion and decay under permanent dental restorations.